First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ Ezurpimtrostat in patients with primary and secondary liver cancers

First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ Ezurpimtrostat in patients with primary and secondary liver cancers

Introduction - GNS561/Ezurpimtrostat is a first-in-class, orally bioavailable, small molecule that blocks cancer cell proliferation by inhibiting late-stage autophagy and dose-dependent build-up of enlarged lysosomes by interacting with the palmitoyl-protein thioesterase 1 (PPT1). Methods - This pha...

Full description

Bibliographic Details
Main Authors: James J. Harding, Ahmad Awada, Gael Roth, Thomas Decaens, Philippe Merle, Nuria Kotecki, Chantal Dreyer, Christelle Ansaldi, Madani Rachid, Soraya Mezouar, Agnes Menut, Eloïne Nadeige Bestion, Valérie Paradis, Philippe Halfon, Ghassan K. Abou-Alfa, Eric Raymond
Format: Article
Language:English
Published: Karger Publishers 2022-02-01
Series:Liver Cancer
Online Access:https://www.karger.com/Article/FullText/522418

Internet

https://www.karger.com/Article/FullText/522418

Similar Items